BGAT抗体;BGAT Antibody—艾普蒂 新品

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue lysate, Primary antibody: P01684(PTPRA Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 90 seconds    

  
  

BGAT (β-1.3-galactosyltransferase) antibodies are autoantibodies targeting the β3GalT5 enzyme, a glycosyltransferase involved in synthesizing glycoconjugates on cell membranes. Initially linked to autoimmune disorders, these antibodies gained attention for their association with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). β3GalT5 participates in glycosylation processes critical for cellular recognition and signaling, particularly in modifying phospholipid structures like cardiolipin. Dysregulation of this enzyme may expose cryptic epitopes, triggering autoantibody production.

Research suggests BGAT antibodies contribute to APS pathology by interfering with anticoagulant mechanisms, promoting thrombosis and pregnancy complications. Their detection, often via ELISA or immunoblotting, complements traditional antiphospholipid antibody testing (e.g., anticardiolipin, lupus anticoagulant), improving diagnostic specificity. However, standardization challenges and variable clinical correlations persist. Recent studies explore their potential role in neuropsychiatric SLE and recurrent miscarriage. While not yet part of routine diagnostics, BGAT antibodies represent emerging biomarkers for understanding autoimmune mechanisms and refining patient stratification. Ongoing research focuses on clarifying their pathogenic mechanisms and therapeutic implications in autoimmune-related thrombotic disorders.